Últimas noticias sobre ArriVent BioPharma (NASDAQ:AVBP) Bolsa

ARRIVENT BIOPHARMA INC

ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

ArriVent BioPharma Inc

ACNT

Ascent Industries Joins Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

On June 28, his 54th birthday, Elon Musk didn't post celebratory photos or <a href="https://www.benzinga.com/topic/elon-musk">launch a new product.</a>
Instead, he launched another blistering denunciation of President Donald Trump's sweeping tax and spending bill, calling it <a href="https://www.benzinga.com/news/politics/25/06/46159125/elon-musk-calls-trumps-megabill-political-suicide-says-it-is-utterly-insane-and-destructive-will-destroy-millions-of-jobs-in-america">"utterly insane and destructive"</a> in a post on X (formerly Twitter)—an attack that reignited a political feud and underscored a deeper ideological rift between two of the most influential figures in American public life.
The legislation in question, nicknamed the <a href="https://www.benzinga.com/news/politics/25/06/46159430/trumps-major-bill-advances-in-senate-amid-late-night-vote-salt-provision-compromise-stirs-controversy">"Big, Beautiful Bill"</a> by the Trump administration, is a nearly 1,000-page proposal that combines deep tax cuts with significant spending reductions and industry-specific subsidies. The bill, which passed the House by a narrow margin in May, is now under intense scrutiny in the Senate, where Republican leaders are racing to meet Trump's self-imposed July 4 deadline.
<ul class="wp-block-list">
<li>Read More: <a href="https://www.benzinga.com/news/education/25/06/46157568/happy-birthday-elon-musk-54-facts-and-figures-about-tesla-spacex-ceo-on-his-54th-birthday">54 Things You Might Not Know About Elon Musk</a></li>
</ul>
The Tesla and SpaceX CEO&#8217;s criticism wasn't subtle. "The latest Senate draft bill will destroy millions of jobs in America and cause immense strategic harm to our country," he wrote in an X post on June 28. "It gives handouts to industries of the past while severely damaging industries of the future".
His comments came just hours before the Senate was scheduled to vote on whether to open debate on the bill. Musk, who previously served as head of the now-defunct Department of Government Efficiency (DOGE), has been increasingly vocal in his opposition since leaving the administration in May.
Musk's latest broadside wasn&#8217;t a one-off outburst. It was the culmination of a month-long escalation that began on June 3, when Musk first labeled the legislation a <a href="https://www.benzinga.com/news/politics/25/06/45757029/elon-musk-slams-congressional-spending-bill-as-a-disgusting-abomination">"disgusting abomination"</a>. What followed was a <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">public unraveling of the Musk-Trump alliance</a>, complete with televised rebukes, social media barbs, and threats to sever political and financial ties.
But beyond the spectacle lies a more consequential question: What does Musk's opposition signal about the future of U.S. economic policy—and the fragile coalition behind it?
What's In The Big, Beautiful Bill?
The legislation combines sweeping tax cuts with deep spending reductions and targeted subsidies for fossil fuels, defense, and border enforcement. It also raises the debt ceiling by $5 trillion—the largest single increase in U.S. history.
While the bill passed the House in May, it has faced turbulence in the Senate, where moderate Republicans have balked at its impact on the deficit and the rollback of clean energy incentives. Musk's intervention has only intensified that pressure.
Musk's critique aligns with concerns raised by economists and industry leaders. Jesse Jenkins, an energy systems engineer at Princeton, called the bill's energy provisions "truly so bad," noting that automakers, utilities, and manufacturers alike oppose them. The Joint Committee on Taxation estimates the bill's tax provisions alone would reduce federal revenue by more than $4 trillion over the next decade.
Read More: <a href="https://www.benzinga.com/news/politics/25/06/46160881/bernie-sanders-slams-trumps-big-beautiful-bill-as-a-gift-for-billionaires-the-most-dangerous-piece-of-legislation-in-modern-history">Bernie Sanders Slams Trump&#8217;s Bill As &#8216;The Most Dangerous Piece of Legislation In Modern History'</a>
According to the Congressional Budget Office (CBO), the bill would increase the federal deficit by more than $3 trillion over the next decade. While proponents argue that the tax cuts will spur growth, critics—including some within the GOP—warn that the deficit impact could be severe.
Musk Warns Of &#8216;Political Suicide For The Republican Party&#8217;
Musk's opposition isn't limited to clean energy. He has framed the bill as a threat to American competitiveness. "It's political suicide for the Republican Party," he wrote, citing a poll by the Tarrance Group that reportedly shows declining support for the bill among independent voters. By favoring legacy sectors like coal and oil, the outspoken entrepreneur argues, the legislation undermines innovation in AI, space, and advanced manufacturing—areas where the U.S. is competing globally.
The tech billionaire&#8217;s opposition carries weight not just because of his platform—he is the most-followed person on X—but because of his political capital. He was the largest individual donor to Trump's 2024 campaign, contributing over $250 million. He also briefly served as head of the Department of Government Efficiency (DOGE), a role in which he led aggressive reductions in the federal workforce and spending cuts.
What Happens Next?
The Senate remains divided. With a razor-thin Republican majority, any defections could derail the bill. Musk's high-profile opposition may embolden moderate GOP senators who are already uneasy about the bill's deficit impact and industry favoritism.
Meanwhile, Musk's birthday broadside has dominated headlines, shifting attention from legislative details to the broader question of who shapes economic policy in 2025: elected officials or billionaire technocrats.
As the Senate prepares for a critical vote, one thing is clear—Musk's birthday wish wasn't for cake or candles. It was for Congress to kill the bill before, in his words, it kills the economy.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">Tesla&#8217;s Europe Sales Slide For 5th Straight Month: Elon Musk-led EV Giant&#8217;s Market Share Shrinks To 1.3%</a></li>
</ul>
Photo: Shutterstock

Economics

Elon Musk's Birthday Wish: Kill The Bill Before It Kills The Economy

MDAI

Spectral AI Submits De Novo 510k Marketing Clearance Application To FDA For DeepView System

Seaport Global analyst Jeff Cantwell initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Buy rating and announces Price Target of $37.

Price Target

Initiation

Analyst Ratings

CHYM

Seaport Global Initiates Coverage On Chime Financial with Buy Rating, Announces Price Target of $37

<ul>
<li>Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz&#xAE; and RhodoLED&#xAE; including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.</li>
<li>Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% - 35% of net sales.</li>
<li>This transaction, coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, is expected to fund Biofrontera Inc. to profitability.</li>
</ul>

BFRI

Biofrontera Inc. Acquires All US Rights To Ameluz And RhodoLED From Former Parent Co. Biofrontera AG, Coupled With $11M Financing Led Bt Existing Investors; Under New Agreement, Effective Royalty Rate Paid By Co. Will Be Reduced To 12% Of Net Sales

Sound Point Capital Management Appoints Dan Fabian As Global CFO, Succeeding Kevin Gerlitz, Effective Immediately

Ferroglobe Included In Russell 2000 And Russell 3000 Indexes Effective June 30, 2025

Benchmark analyst David Williams reiterates IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and maintains $50 price target.

Reiteration

IONQ

Benchmark Reiterates Buy on IonQ, Maintains $50 Price Target

METC

Ramaco Resources To Release Updated Information Including Prelim. Economics For Its Brook Mine Rare Earth and Critical Minerals Project On Jul. 1 Before 9: 00 a.m. EST

In the preceding three months, 12 analysts have released ratings for Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.5, along with a high estimate of $39.00 and a low estimate of $14.00. Surpassing the previous average price target of $19.00, the current average has increased by 7.89%.
<img src="https://www.benzinga.com/files/images/story/2025/1751284821_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Magnite among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Magnite. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Magnite compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Magnite's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Magnite's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MGNI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Magnite analyst ratings.</a>
<h2>Unveiling the Story Behind Magnite</h2>
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
<h3>Magnite's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Magnite displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.32%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Magnite's net margin excels beyond industry benchmarks, reaching -6.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Magnite's ROE stands out, surpassing industry averages. With an impressive ROE of -1.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.35%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.83, Magnite adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MGNI

12 Analysts Assess Magnite: What You Need To Know

Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) is currently in Phase 11 of its 18-phase Adhishthana Cycle. The stock&#8217;s structure remains bullishly intact according to the Adhishthana framework. Here&#8217;s a breakdown of what triggered the move and where the stock is likely headed next.
<h3 class="wp-block-heading">Why Did VST Start Rallying in November 2023?</h3>
According to the Adhishthana Principles, Phases 4 through 8 typically form the Adhishthana Cakra, a bullish arc or channel structure that serves as a preparatory foundation. A breakout in Phase 9 often marks the beginning of a supreme bullish move and initiates what is known as the Himalayan Formation.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="895" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana.png" alt="Fig.1 VST Cakra Breakout (Source: Adhishthana.com)" class="wp-image-15074" style="width:638px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana-300x224.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana-1024x764.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105156/VST-Weekly-Chart-Cakra-Adhishthana-768x573.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 VST Cakra Breakout (Source: Adhishthana.com)</figcaption></figure>
In VST's case, the setup followed the framework precisely. After constructing the Adhishthana Cakra, the stock broke out in Phase 9, rallying by approximately 233%. This breakout was the foundational move that triggered its ongoing ascent and marked the beginning of the Himalayan Formation.
<h3 class="wp-block-heading">VST&#8217;s Phase 10: The Peak Attempt</h3>
During Phase 10, stocks generally make their first attempt at a peak. VST followed suit, hitting a high of $199.84 on the 31st bar of the phase. Although it experienced a brief decline afterward, the stock never breached its Phase 9 mid or low levels, indicating the structure of ascent was still intact.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"When analysing the Himālaya move during C10, it is crucial to consider the C9 levels (High/Mid/Low)—if these key levels remain unbroken, the ascent continues." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
<h3 class="wp-block-heading">VST&#8217;s Phase 11: Ascent Still Underway</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="882" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana-.png" alt="Fig.2 VST's Phases 9, 10 &amp; 11 (Source: Adhishthana.com)" class="wp-image-15075" style="width:480px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana--300x221.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana--1024x753.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105339/VST-Current-Weekly-Phase-Adhishthana--768x564.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 VST&#8217;s Phases 9, 10 &amp; 11 (Source: Adhishthana.com)</figcaption></figure>
With the ascent structure still intact, VST has continued its upward trajectory since entering Phase 11, already gaining 91%. This sustained momentum increases the likelihood that the stock will surpass its previous Phase 10 high of $199.84 during the current phase.
Phase 11 concludes on May 3, 2026, leaving ample room for the stock to form its Himalayan peak. While a peak typically occurs in this phase, in some rare cases where the structure remains firm without a conclusive top, a peak can emerge in Phase 12 instead.
<h3 class="wp-block-heading">Monthly Chart Confirms Bullish Move</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1078" height="818" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana.png" alt="Fig.3 VST Monthly Chart (Source: Adhishthana.com)" class="wp-image-15076" style="width:550px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana.png 1078w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana-300x228.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana-1024x777.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30105424/VST-Monthly-Phase-2-Chart-Adhishthana-768x583.png 768w" sizes="(max-width: 1078px) 100vw, 1078px" /><figcaption class="wp-element-caption">Fig.3 VST Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
VST began its Buddhi rally on the monthly timeframe on May 1, 2024. Since then, the stock has already appreciated by roughly 192%, once again aligning well with the expectations set by the Adhishthana Principles.
This monthly Phase 2 continues until March 31, 2027, further supporting the view that bullish momentum remains intact for the foreseeable future.
<h3 class="wp-block-heading">Investor Takeaway: Let the Rally &amp; Peak Unfold</h3>
If you currently hold VST in your portfolio, the Adhishthana structure suggests you should continue holding. The stock has not yet formed its peak, and the bullish formation remains active. Any visible signs of a peak will appear only after a clear structural break, which has not occurred yet. Until then, VST appears poised to take out its previous high and continue its ascent.

Equities

Technicals

Opinion

Signals

Vistra's Rally Explained: Where Is The Stock Headed Next

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

OMER

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), saying he wants to own more Okta.
On the earnings front, Okta, on May 27, reported first-quarter revenue of $688 million, beating analyst estimates of $680.25 million. The company reported adjusted earnings of 86 cents per share, beating analyst estimates of 77 cents per share.
Cramer said he is not going to trust Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>).
DA Davidson analyst Alex Platt, on June 16, maintained Nebius Group with a Buy rating and raised the price target from $50 to $55.
Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) is down 57%, and it is not making money, Cramer said.
Supporting his view, JP Morgan analyst Rahul Krotthapalli, on June 25, maintained Sweetgreen with a Neutral rating and lowered the price target from $20 to $16.
Cramer said Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) is &#8220;just one smoking hot stock.&#8221;
Lending support to his choice, Wells Fargo analyst Chris Carey, on June 13, maintained Monster Beverage with an Overweight rating and raised the price target from $67 to $70.
Cramer said it's the time to buy McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>). &#8220;I've been saying that you must own McDonald's here,&#8221; he added.
In an official announcement last Tuesday, McDonald's and Krispy Kreme Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) have decided to part ways. Concerns about profitability led to the termination of this association. Their U.S. doughnut partnership is set to conclude on July 2, 2025. 
Price Action:
<ul class="wp-block-list">
<li>Nebius shares fell 1.4% to settle at $51.84 on Friday.</li>
<li>Sweetgreen shares declined 0.4% to close at $13.59.</li>
<li>McDonald's shares gained 2.1% to settle at $291.55 during the session.</li>
<li>Monster Beverage fell 0.8% to settle at $61.71 on Friday.</li>
<li>Okta shares gained 0.3% to close at $98.43.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

DNUT

MNST

NBIS

OKTA

Cramer Praises Monster Beverage As 'Smoking Hot,' Warns Investors About This AI Stock

HPE: 14% &#x7C; <a href="https://www.benzinga.com//node/46165707">Hewlett Packard Enterprise shares are trading higher after the company and Juniper Networks reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, clearing the way for the deal to close.</a>
&nbsp;
VERO: 59% &#x7C; <a href="https://www.benzinga.com//node/46153651">Venus Concept shares are trading higher after Madryn Asset Management increased its stake in the company to 85.5%.</a>
&nbsp;
WBUY: 64% &#x7C; <a href="https://www.benzinga.com//node/46165253">Webuy Global Partners With Coinbase Commerce To Launch Stablecoin Payment Option For Global Travel And E-Commerce Offerings</a>

VERO

WBUY

Market-Moving News for June 30th

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans
First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market
SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in preclinical studies.
Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD study enrolled 49 subjects.
The key findings include:
<ul>
<li>Excellent Safety Results: All adverse events (AEs) were mild, transient, and self-resolving. No drug-related AEs were observed in the blinded dataset, and no tolerability issues or safety signals were detected across multiple assessments (vital signs, ECGs, clinical laboratory tests, physical examinations, and visual analogue mood scales).</li>
<li>Predictable PK: Full dose-exposure profiles were successfully explored. Plasma analysis confirmed dose-dependent, linear absorption across the evaluated range.</li>
<li>Therapeutic Window: A wide safety margin was observed between estimated therapeutic plasma concentrations and the highest exposure levels achieved, supporting potential titration for maximum efficacy in future studies.</li>
</ul>

ARTL

Artelo Biosciences Announces Results From Its First-In-Human Study Evaluating ART26.12, Inhibitor Of FABP5; Says Results Affirm Safety And PK Profile Previously Observed In Preclinical Studies

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

Stifel analyst Brad Reback upgrades Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) from Hold to Buy and raises the price target from $180 to $250.

Upgrades

ORCL

Stifel Upgrades Oracle to Buy, Raises Price Target to $250

WIIM

JNPR

Juniper Networks shares are trading higher after the company and Hewlett Packard Enterprise reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, paving the way for the transaction to close.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/27/final-trades-kkr-co-lululemon-meta-and-rockwell-automation.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington, managing partner of Requisite Capital Management, said KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) is in big-time fundraising mode. The stock will go <a href="https://www.benzinga.com/quote/KKR">higher, she added</a>.
As per the recent news, Torrent Pharma, on Sunday, announced plans to acquire a controlling stake in JB Chemicals from KKR at INR 25,689 Cr valuation.
Brian Belski, chief investment strategist at BMO Capital Markets, said Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is quickly becoming a value stock again.
Lululemon Athletica reported a mixed shelf offering on June 26.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson, Capital Wealth Planning founder and CIO, named Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) as his final trade.
Supporting his view, Piper Sandler analyst Thomas Champion, on June 27, reiterated Meta Platforms with an Overweight rating and raised the price target from $650 to $808.
Stephanie Link, chief investment strategist and portfolio manager at Hightower, picked Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as her final trade.
Lending support to her choice, Keybanc analyst Ken Newman, on June 13, maintained Rockwell Automation with an Overweight rating and raised the price target from $345 to $360.
Price Action:
<ul class="wp-block-list">
<li>KKR shares gained 1.8% to close at $134.29 on Friday.</li>
<li>lululemon rose 1.5% to settle at $235.02 during the session.</li>
<li>Meta shares gained 1% to close at $733.63 on Friday.</li>
<li>Rockwell Automation shares gained 1.2% to settle at $329.95.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a></li>
</ul>
Photo: Shutterstock

LULU

Meta, KKR, Lululemon And An Industrial Stock On CNBC's 'Final Trades'

Hewlett Packard Enterprise shares are trading higher after the company and Juniper Networks reached an agreement with the U.S. Department of Justice to resolve its lawsuit challenging HPE's acquisition of Juniper, clearing the way for the deal to close.

Health Care

Press Releases

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Earnings

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

Contracts

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent BioPharma Reports Full Year 2024 Financial Results

Management

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ArriVent BioPharma Reports First Quarter 2025 Financial Results

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Comments

ArriVent BioPharma

Noticias

Últimas noticias sobre ArriVent BioPharma (NASDAQ:AVBP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL